Teva Pharmaceutical Industries Ltd
—- Market cap
- —
- Debt
- —
- Cash
- —
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: Teva Pharmaceutical Industries Ltd stock price vs BG: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at BG's multiple
Needs EPS (TTM), BG P/E.
Implied fair value · at Teva Pharmaceutical Industries Ltd's multiple
Needs Teva Pharmaceutical Industries Ltd P/E.
Engine logicTeva Pharmaceutical Industries Ltdvalued onBG’smultiple
Metric by metric
Snapshot Sep 4, 4:00 PM ET
Where each company leads, and how wide the gap is.
Higher is better
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: Teva Pharmaceutical Industries Ltd Latest annual filing · BG FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 67% equity / 33% debt · EV / Revenue 0.46x · EV / EBITDA 13.90x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
TEVA PHARMACEUTICAL INDUSTRIES LTD · implied price per share
Reporting currency could not be verified.
BUNGE GLOBAL SA · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Teva Pharmaceutical Industries Ltd · not enough data.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
—
0.66x
Net debt / EBITDA
Leverage against operating earnings
—
4.06x
Cash and equivalents
Liquid reserves on the balance sheet
—
$2.00B
Total debt
Interest-bearing obligations outstanding
—
$11.51B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Archer-Daniels-Midland Co
Teva Pharmaceutical Industries Ltd vs ADM
Ingredion Inc
Teva Pharmaceutical Industries Ltd vs INGR
URANIUM ENERGY CORP
Teva Pharmaceutical Industries Ltd vs UEC
Andersons, Inc.
Teva Pharmaceutical Industries Ltd vs ANDE
CVR ENERGY INC
Teva Pharmaceutical Industries Ltd vs CVI
FRESH DEL MONTE PRODUCE INC
Teva Pharmaceutical Industries Ltd vs FDP
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.